Table 6 Risk of dyslipidemia across tertiles of lycopene consumption in participants of Tehran Lipid and Glucose Study.
Lycopene consumption (mcg/day) | T 1 | T 2 | T 3 | P for trend |
|---|---|---|---|---|
High-TG | ||||
Range of lycopene consumption (mcg/d) | ≤ 2190.3 | 2190.4-4216.8 | ≥ 4216-9 | |
Participants/ cases (n/n) | 432/178 | 427/152 | 420/165 | |
Crude | 1.00 | 0.82 (0.66–1.02) | 0.92 (0.74–1.14) | 0.501 |
Model 1 | 1.00 | 0.77 (0.62–0.96) | 0.87 (0.70–1.08) | 0.279 |
Model 2 | 1.00 | 0.77 (0.63–0.97) | 0.88 (0.69–1.11) | 0.342 |
High-LDL | ||||
Range of lycopene consumption (mcg/d) | ≤ 2221.8 | 2221.9-4210.7 | ≥ 4210.8 | |
Participants/ cases (n/n) | 443/159 | 450/178 | 433/163 | |
Crude | 1.00 | 1.16 (0.93–1.45) | 1.03 (0.82–1.29) | 0.896 |
Model 1 | 1.00 | 1.06 (0.85–1.33) | 0.97 (0.85–1.21) | 0.723 |
Model 2 | 1.00 | 1.11 (0.88–1.39) | 1.09 (0.85–1.39) | 0.516 |
High-total cholesterol | ||||
Range of lycopene consumption (mcg/d) | ≤ 2161.1 | 2161.2-4190.4 | ≥ 4190.5 | |
Participants/ cases (n/n) | 452/203 | 437/199 | 422/188 | |
Crude | 1.00 | 1.05 (0.85–1.28) | 0.93 (0.76–1.15) | 0.488 |
Model 1 | 1.00 | 0.97 (0.79–1.18) | 0.87 (0.71–1.07) | 0.195 |
Model 2 | 1.00 | 1.01 (0.82–1.24) | 0.96 (0.77–1.21) | 0.744 |
Low-HDL | ||||
Range of lycopene consumption (mcg/d) | ≤ 2191.4 | 2191.5-4239.1 | ≥ 4239.2 | |
Participants/ cases (n/n) | 244/94 | 231/73 | 236/87 | |
Crude | 1.00 | 0.81 (0.59–1.11) | 0.96 (0.71–1.30) | 0.883 |
Model 1 | 1.00 | 0.80 (0.58–1.10) | 0.97 (0.72–1.32) | 0.925 |
Model 2 | 1.00 | 0.78 (0.56–1.07) | 0.92 (0.67–1.26) | 0.679 |
